# Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)

> **NCT00337428** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 843 (actual)

## Conditions studied

- Neoplasms, Glandular and Epithelial
- Diphtheria
- Tetanus
- Whooping Cough
- Poliomyelitis

## Interventions

- **BIOLOGICAL:** Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Current Manufacturing Facility (CMF)
- **BIOLOGICAL:** Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Future Manufacturing Facility (FMF)
- **BIOLOGICAL:** Comparator: REPEVAX™ (Concomitant)
- **BIOLOGICAL:** Comparator: REPEVAX™ (Non-Concomitant)

## Key facts

- **NCT ID:** NCT00337428
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** 843 (ACTUAL)
- **Last updated:** 2016-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00337428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00337428, "Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00337428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*